Clinicopathologic characteristics and prognosis comparison of the uterine high grade endometrial carcinomas

Objectives: Grade 3 endometrioid adenocarcinomas (G3 EAC), type two endometrial carcinomas (Type 2 EC), and alsouterine carcinosarcomas (UCS) are considered as high-grade endometrial adenocarcinomas. The aim of this study was tocompare the clinicopathologic features and survival of patients with UCS, G3 EAC, Type2 EC.Material and methods: We included two hundred and thirty-five patients in this study. Patients were divided into threegroups according to the type of tumor as uterine G3 EAC (group 1, n = 62), Type 2 EC (serous, clear and mixed types; group 2,n = 93), and UCS (group 3, n = 80). We compared the groups according to age, initial symptom, surgical approach, stage,myometrial invasion (MI), lymph node invasion (LNI), lymphovascular space invasion (LVSI), adjuvant therapy, and survival.When comparing the survival outcomes the Kaplan-Meier analysis was performed.Results: The groups were similar according to age, menopausal status, nulliparity, initial symptoms, stage, LVSI, and LNI.Positive cytology was determined significantly more in group 3. There was a significant difference between the groups interms of myometrial invasion degree. Optimal cytoreduction was similar among the groups. The primary adjuvant treatmentwas chemotherapy for UCS and Type2 EAC whereas radiotherapy was the main adjuvant treatment for G3 EAC. Therewere no significant differences among the groups according to overall survival (OS) (p = 0.290).Conclusions: Although the survival difference among the groups can not be revealed, these patients have different clinicaland pathological features and they should be considered as different groups

Multifocal Epitheloid Hemangioendothelioma: A Case Report

Epitheloid hemangioendothelioma (EHE) is a rare vascular tumor with malignant biological behavior. It arises from vascular endothelial cells, usually within soft tissues, and can occur in almost all locations, but tumor can be found in liver, lungs, bone and skin. It is considered to be a low or borderline malignant tumor with, usually, slow progression, but aggressive forms have been described. We present a 24 year-old female case of multifocal epitheloid hemangioendothelioma of the soft tissue with its clinical, radiological and histopathological findings [Cukurova Med J 2014; 39(2.000): 383-386

Chromosomal aberrations in multiple myeloma: clinical outcome and response to bortezomib

WOS: 000480626400012Purpose: Multiple myeloma is a heterogeneous disease, for which an understanding of the prognostic and predictive value of chromosomal aberrations is necessary to prescribe the most appropriate therapy. We aimed to document the frequencies of chromosomal aberrations in our institute and searched the relationships between therapy regimens and chromosomal aberrations. Materials and Methods: We analyzed the frequency of del(17p13), del(13q14), t(11;14), and t(4; 14) in patients with MM by interphase-fluorescent in situ hybridization who were diagnosed between January 2010 and December 2015 in our institute. We researched the relationship between response to conventional chemotherapy and Bortezomib based chemotherapy. Results: Eighty patients (72.7%) had at least one chromosomal aberration. The most frequently observed aberration was del(17p13) (48.2%), followed by del(13q14) (40.9%), t(11; 14) (16.4%), and t(4; 14) (11.8%). In clinically analyzed subgroup (n=67), 36 patients who received Bortezomib based chemotherapy showed a higher response rate (55.6%) than conventional chemotherapy group (48.4%). With respect to chromosomal aberrations, response rates were higher in Bortezomib based therapy group (63.2%) than conventional chemotherapy group (50%) in del (17p13) positive patients as well as in del (13q14) positive patients (61.5% in Bortezomib based, 50% in conventional chemotherapy group). Conclusion: Bortezomib-containing regimens may have beneficial effects on the clinical outcome of patients with del (17p13) and del (13q14)

Expression of bcl-2, bcl-6, HIF, HGF, c-kit, neu/cerb2 and VEGF-C in nasopharyngeal carcinoma

30th Congress of the European-Society-for-Medical-Oncology -- SEP 29-OCT 03, 2006 -- Istanbul, TURKEYWOS: 000248078900622…European Soc Med Onco

Histopathologic subtypes of pediatric lymphomas and relation to Ebstein-Barr virus: an immunohistochemical and in-situ hybridization study

WOS: 000437951900014Purpose: The aim of this study was toexplore the histopathologic subtypes of pediatric lymphomas and their relation with Ebstein-Barr virus infection in our region. Materials and Methods: In this retrospective study, 87 children including 36 cases with Hodgkin lymphoma and 51 cases with non-Hodgkin lymphoma were included in the study. The pathologic slides were used to investigate immunohistochemical staining with ebstein-barr virus latent membrane protein-1 and in-situ hybridization. Results: The most common histopathological subtype in hodgkin lymphoma cases was mixed cellular classical hodgkin lymphoma (55.6%). The most common histopathological subtype in Non-Hodgkin lymphoma cases was Burkitt lymphoma (51.0%). Ebstein-Barr virus latent membrane protein-1 was positive in 29 Hodgkin lymphoma. All non-Hodgkin lymphoma cases were stained negative with immunohistochemical. The positive staining rate of Hodgkin lymphoma cases with in-situ hybridization was 83.3% and this rate was 27.5% in non-Hodgkin lymphoma cases. The differences between groups for both staining methods were significant. Conclusion: The results of this study show that the distribution of histopatholojik subtypes of pediatric lymphomas similar to in developing countries. And we have observed that in-situ hybridization is more specific than immunohistochemistry because Ebstein-Barr virus positivity is more detected in in-situ hybridization

Are Uterine Grade 3 Endometrioid Adenocarcinoma and Carcinosarcoma Really Clinically Similar?

WOS: 000469053500001PurposeThe aim of this study was to compare the clinical characteristics and outcomes of the cases with uterine high-grade endometrioid adenocarcinoma (HGEAC) and uterine carcinosarcoma (UCS).MethodsA total of 141 patients were included in this study. Of them, 61 cases had uterine HGEAC (group 1) and 80 had UCS (group 2). Both groups were compared in terms of clinical and pathological characteristics including age, stage, initial symptom, surgical approach, myometrial invasion, lymphovascular space invasion (LVSI), lymph node invasion, adjuvant therapy, and survival. The Kaplan-Meier and Cox proportional hazards models were used to compare the outcomes and prognostic factors.ResultsThere were no statistically significant differences between the groups with regard to age, nulliparity, menopausal status, and the main initial symptom. Both groups were similar in terms of stage, depth of myometrial invasion, and lymph node metastasis. Lymphadenectomy was performed in 74% and 91% of the cases in group 1 and group 2, respectively (p<0.001). LVSI was found to be more frequent in group 1 (p=0.032); however, in group 2, positive cytology was more common (p=0.008). Chemotherapy was the main adjuvant therapy for UCS, while radiotherapy was the main adjuvant therapy for HGEAC. There was no difference between the groups in terms of disease-free survival (DFS); however, overall survival (OS) was found to be longer in group 1 (p=0.029). Histopathologic type and LVSI were determined as independent predictive factors for OS.ConclusionUCSs are clinically more aggressive than HGEAC and should be considered as a separate group of tumors

Effect of neoadjuvant chemotherapy on estrogen receptor, progesterone receptor, Cerb-B-2, vascular endothelial growth factor and Ki-67 in patients with locally advanced breast cancer

WOS: 000458742100030Purpose: The aim of this study is aimed to demonstrate the changes in the tumor diameter and expressions of vascular endothelial growth factor (VEGF), estrogen receptor (ER), progesterone receptor (PR), Ki-67, and Cerb-B2 status after neoadjuvant chemotherapy in the patients with locally advanced breast cancer. Materials and Methods: Sixty-nine patients who diagnosed with locally advanced breast cancer and treated with were prospectively evaluated. The tumor diameter and VEGF, Ki-67, ER, PR, and Cerb-B2 expressions tested by immunohistochemistry (IHC) were evaluated before and after neoadjuvant chemotherapy. Results: There was a statistically significant reduction in the tumor diameter and in the expression of VEGF, Ki-67, ER, PR, and Cerb-B2 after neoadjuvant chemotherapy. Conclusion: The significant reduction in VEGF expression suggests that the tumor angiogenesis and its metastatic ability may be reduced by neoadjuvant chemotherapy. The significant change in the Ki-67 proliferation index may suggest the reduced proliferative activity of malignant cells with neoadjuvant chemotherapy

The Discordance Between HER-2/NEU Expression Assessed by Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH): Is It Important to Detect?

Purpose: Assessment of HER-2 has become of great importance following the advent of HER-2 antibody treatment. Use of trastuzumab therapy depends on the assessment of HER-2 via standard immunohistochemistry (IHC) assays for protein overexpression or via fluorescence in situ hybridization (FISH) for gene amplification. The aim of this study was to determine the rate of discordance between FISH and IHC in our hospital. The rate of discordance varies from hospital to hospital, and due to certain staff, technical, and biological reasons, IHC and FISH may not be concordant in every patient. It is important to determine the rate of discordance between these 2 methods and attempt to lower it. In addition to the rate of discordance, we also investigated the reasons for the discordance and what affect it has on the progression of the disease and treatment. Material and Methods: A total of 79 patients with breast cancer were assessed for HER-2 protein expression via IHC and HER-2 gene amplification via FISH. Results: Among these 79 patients, 47 (59.5%) were FISH (&#150;) and 32 (40.5%) were FISH (+), whereas FISH was negative in 8 (10.4%) patients that were HER-2 (3+) and FISH was positive in 9 (11.4%) patients that were HER-2 (1+). The discordance rate was 21.5%. Conclusion: The clinical implication of this discordance rate and it\'s affect on the choice of appropriate therapy are of critical importance. As such, it would be beneficial for each hospital to determine its own discordance rate

Impacts of beta-estradiol on intestinal injury in newborn rats

WOS: 000373516000011PubMed ID: 26305144Objective: Necrotizing enterocolitis has been investigated and debated extensively in recent years; however, there is still no effective treatment. The aim of this study was thus to examine the effects of -estradiol on intestinal injury in rats.Methods: Twenty-four newborn female rat pups were divided into three groups. In group 1 (sham), hypoxia-re-oxygenation was not performed. In group 2 (saline), the rats were injected with saline after hypoxia-re-oxygenation, and the process was repeated for 5d. In group 3 (-estradiol treatment), the rats were subjected to hypoxia-re-oxygenation and then given -estradiol intraperitoneally once a day for 5d. After these procedures, the terminal ileum was removed for analysis.Results: Statistically significant differences in histological grades were found between groups 1 and 2 (p=0.000), groups 1 and 3 (p=0.028), and groups 2 and 3 (p=0.021). There were also differences in TNF- and IL-6 levels between groups 2 and 3 (p=0.000 and p=0.038, respectively) and between groups 1 and 2 (p=0.000 and p=0.000); there was no difference between groups 1 and 3 (p=0.574 and p=0.195, respectively). Electron microscopy examination revealed a decrease in lipid droplets at the apical cytoplasm of the columnar cells in group 2; in group 3, the absorption of the lipids as lipid droplets was similar to that of group 1.Conclusion: In this study, -estradiol was found to decrease the intensity of intestinal injury significantly by inhibiting TNF- and IL-6